12/17
04:05 pm
slno
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
Medium
Report
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
12/4
12:10 pm
slno
Indo US Bridging RARE Summit Highlights Patient Stories, Affordable Innovation, and Calls for Global Collaborations
Low
Report
Indo US Bridging RARE Summit Highlights Patient Stories, Affordable Innovation, and Calls for Global Collaborations
12/2
10:14 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $74.00 price target on the stock.
Low
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $74.00 price target on the stock.
12/2
08:06 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Medium
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
12/2
08:06 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "outperform" rating re-affirmed by analysts at Robert W. Baird. They now have a $72.00 price target on the stock.
Medium
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "outperform" rating re-affirmed by analysts at Robert W. Baird. They now have a $72.00 price target on the stock.
11/27
08:00 am
slno
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Medium
Report
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
11/26
08:30 am
slno
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Medium
Report
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
11/14
04:05 pm
slno
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
Medium
Report
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
11/12
06:07 am
slno
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation [Yahoo! Finance]
Medium
Report
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation [Yahoo! Finance]
11/11
08:10 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Low
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
11/6
04:22 pm
slno
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/6
04:05 pm
slno
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Low
Report
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
10/28
09:26 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $73.00. They now have an "outperform" rating on the stock.
Low
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $73.00. They now have an "outperform" rating on the stock.
10/28
08:00 am
slno
Soleno Therapeutics to Participate in Upcoming November Investor Conferences
Low
Report
Soleno Therapeutics to Participate in Upcoming November Investor Conferences
10/21
08:00 am
slno
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
Low
Report
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
10/15
06:16 pm
slno
Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment [Yahoo! Finance]
Low
Report
Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment [Yahoo! Finance]
10/8
06:43 pm
slno
Why Soleno Therapeutics Stock Blasted 9% Higher Today [Yahoo! Finance]
Low
Report
Why Soleno Therapeutics Stock Blasted 9% Higher Today [Yahoo! Finance]
10/8
08:30 am
slno
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
Medium
Report
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome